DCVax-L is under clinical development by Northwest Biotherapeutics and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DCVax-L’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
DCVax-L overview
DCVax-L contains autologous, antigen-presenting dendritic cells. It is formulated as a suspension for an intradermal route of administration. DCVax-L is indicated for the adjuvant treatment of glioma brain cancers (both Glioblastoma multiforme and lower grade gliomas) in adults after tumor resection and standard therapy (Chemo and or radiotherapy).
DCVax-L is under development for the treatment of newly diagnosed unilateral glioblastoma (Grade IV), recurrent glioblastoma multiforme, gliosarcoma, oligodendroglioma, small cell glioblastoma, giant cell glioblastoma, and colorectal cancer with liver metastases. It is also under development for metastatic ovarian cancer, epithelial ovarian cancer and peritoneal cancer.
Northwest Biotherapeutics overview
Northwest Biotherapeutics (NW Bio) is a development-stage biotechnology company. It discovers and develops immunotherapy products to treat cancer. The company uses its proprietary technology platform, DCVax to develop therapeutic product candidates. DCVax is a personalized immune therapy and consists of therapeutic vaccine which uses patient’s own dendritic cells as the therapeutic agent. NW Bio’s product lines include DCVax-L, for the treatment of glioblastoma multiforme (GBM), brain cancer; DCVax-Direct, for the treatment of all inoperable solid tumor cancers; and DCVax-Prostate, for the treatment of late-stage prostate cancer. NW Bio is headquartered in Bethesda, Maryland, the US.
For a complete picture of DCVax-L’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
